TABLE 3.
Clinical and demographic characteristics of patients with symptomatic EBV infections
| Patient no. | Age (yr)/sexa | Type of transplant | No. of yrs posttransplantation | EBV DNA level (GE/0.5 μg of PBMC DNA) | Clinical symptom(s)b | Treatmentc | Outcome |
|---|---|---|---|---|---|---|---|
| 1 | 46/F | Heart | 5 | 100 | FI, LFTa, leukopenia | ↓ISR | Improved |
| 2 | 62/M | Heart | 10 | 3,000 | FI | ↓ISR | Improved |
| 3 | 62/M | Heart | 5 | 5,000 | NHL | ↓ISR, IFN-α | Dead |
| 4 | 60/F | Liver | 1 | 100 | LFTa | ↓ISR | Improved |
| 5 | 65/M | Heart | 9 | 11,520 | FI | Stop ISR | Improved |
| 6 | 59/M | Heart | 7 | 7,500 | FI | ↓ISR | Improved |
| 7 | 42/M | Heart | 5 | 126,000 | MOI | Stop ISR, ACV | Dead |
| 8 | 60/M | Heart | 8 | 1,000 | FI | ↓ISR | Improved |
| 9 | 51/M | Heart | 3 | 1,200 | FI | ↓ISR | Improved |
| 10 | 46/M | Heart | 8 | 11,200 | MOI | ↓ISR, IFN-α | Dead |
| 11 | 10/F | Heart | 2 | 10,000 | NHL | ↓ISR, ACV | Dead |
| 12 | 67/M | Heart | 6 | 7,000 | Multiple lymph node involvement | ↓ISR, ACV | Dead |
| 13 | 18/F | Heart | 4 | 223 | NHL | ↓ISR, ACV | Improved |
| 14 | 21/M | Heart | 2 | 8,300 | NHL | ↓ISR, ACV | Improved |
| 15 | 21/M | Heart | 7 | 8,570 | NHL | ↓ISR, ACV | Dead |
a
M, male, F, female.
b
FI, febrile illness; LFTa, liver function test abnormalities; MOI, multiple organ involvement.
c
↓ISR, immunosuppressive regimen reduction; IFN-α, alpha interferon; ACV, acyclovir.